|
7th Annual Conference Of The British HIV Association [BHIVA]27 – 29 April 2001, The Hove Centre, Brighton |
[AUTHOR(S):] D Pillay1, CA Sabin2, on behalf of the Amprenavir Expanded Access Programme
1 Public Health Laboratory Service and University of Birmingham, 2 Royal Free and University College Medical School, London, UK
BHIVA Conf 2001 Apr 27-29;7:O5
OBJECTIVE: To assess response rates to regimens including amprenavir (APV) in heavily pretreated patients.
METHODS: A retrospective case-note review and resistance substudy of all patients receiving APV from 17 clinical centres in the UK.
RESULTS: We studied 84 patients (91% male, 68% homo/bisexual, median age 37.5 years). The patients had a median CD4 count and RNA level at baseline of 109 (range 2–580) cells/µl and 5.05 (1.70–6.22) log10 HIV-1 RNA copies/ml, respectively. This was a highly drugexperienced population (median number of drugs exposed to: nine; 94% exposed to protease inhibitors, 81% to non-nucleoside reverse transcriptase inhibitors). The patients had first started antiretroviral therapy 4.0 (0-11.2) years before starting APV. Adherence was good in only 49% of patients, and at baseline the patients had a median of five (0-12) reverse transcriptase mutations and five (1-7) protease mutations. By 6 months after starting APV, viral loads had dropped in 60%, increased in 37% and remained stable in 3%. The median drop in viral load was 0.37 (3.83 to –1.01) log10 copies/ml. CD4 counts had increased in 65%, decreased in 30% and remained stable in 5%, with a median CD4 increase of 10 (–370 to 245) cells/µl. The patients remained on their first course of APV for a median of 8.2 (0.1–38.8) months; 56% of patients stopped their first course of APV, the main reasons being adverse reactions to at least one drug in the regimen, and treatment failure. Clinical and virological predictors of response will be presented.
DISCUSSION: In a highly drug-experienced population with multiple drug resistance, APV-containing regimens can lead to short-term virological benefit in the majority of patients.
PRESENTING AUTHOR: D Pillay
010427
O5
Copyright © 2001 - British HIV Association (BHIVA) Reproduction of this abstract (other than one copy for personal reference) must be cleared through the BHIVA Organising Secretariat 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD